A Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-, Ascending-Dose Study of the Safety, Tolerability and Pharmacokinetics of TQS-168 in Healthy Male Adults
Latest Information Update: 29 Apr 2022
At a glance
- Drugs TQS 168 (Primary)
- Indications Amyotrophic lateral sclerosis; Dementia
- Focus Adverse reactions; First in man
- Sponsors Tranquis Therapeutics
Most Recent Events
- 29 Apr 2022 Status changed from recruiting to completed.
- 10 Mar 2022 Planned number of patients changed from 68 to 78.
- 09 Mar 2022 Status changed from active, no longer recruiting to recruiting.